干扰素治疗慢性乙型肝炎的分子机制研究进展  

Advance in molecular mechanism of interferon to treat chronic hepatitis B

作　　者：刘汉屈[1] 秦波[1] 

机构地区：[1]重庆医科大学附属第一医院感染科,重庆市400010

出　　处：《世界华人消化杂志》2009年第18期1803-1808,共6页World Chinese Journal of Digestology

摘　　要：IFN-α治疗慢性乙型肝炎的反应不仅与治疗前HBV DNA载量、HBV基因型、HBV基因组的点突变以及宿主Ⅱ类HLA基因的多态性等因素有关,而且也与患者免疫状况有关,病毒突变株及基因表型日益受到关注.IFN抗HBV的作用机制及HBV逃逸IFN治疗的机制尚未完全明确.本文从基因、蛋白质和细胞等方面对相关影响因素及机制进行综述.The antiviral efficacy of interferon-α （IFN-α） therapy for chronic hepatitis B （CHB） is not only related to DNA load and genetype of HBV before treatment, gene mutation of HBV and polymorphism of type II HLA in the host, but also depends on the immunity of CHB patients. Researchers pay more and more attention to the mutant strain of virus and phenotypes of genes. However, the mechanism of interferon to resist HBV and the escape mechanism of HBV against the IFN therapy have not been clarified yet. This paper reviews the mechanism of IFN therapy and the influencing factors at molecular and genetic levels.

关 键 词：干扰素 慢性乙型肝炎 治疗 基因 

分 类 号：R512.62[医药卫生—内科学] R581.1[医药卫生—临床医学]